Boston Scientific Corporation $BSX is Headland Capital LLC’s 6th Largest Position

Headland Capital LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 1.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 89,704 shares of the medical equipment provider’s stock after purchasing an additional 1,441 shares during the period. Boston Scientific accounts for 4.1% of Headland Capital LLC’s investment portfolio, making the stock its 6th biggest position. Headland Capital LLC’s holdings in Boston Scientific were worth $9,635,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. Brighton Jones LLC grew its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the period. Procyon Advisors LLC grew its position in shares of Boston Scientific by 104.4% in the first quarter. Procyon Advisors LLC now owns 4,765 shares of the medical equipment provider’s stock valued at $481,000 after purchasing an additional 2,434 shares during the period. Sivia Capital Partners LLC grew its position in shares of Boston Scientific by 16.7% in the first quarter. Sivia Capital Partners LLC now owns 4,424 shares of the medical equipment provider’s stock valued at $446,000 after purchasing an additional 632 shares during the period. UMB Bank n.a. grew its position in shares of Boston Scientific by 76.7% in the first quarter. UMB Bank n.a. now owns 72,075 shares of the medical equipment provider’s stock valued at $7,271,000 after purchasing an additional 31,276 shares during the period. Finally, Wedmont Private Capital grew its position in shares of Boston Scientific by 6.5% in the first quarter. Wedmont Private Capital now owns 21,555 shares of the medical equipment provider’s stock valued at $2,019,000 after purchasing an additional 1,319 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BSX. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday. UBS Group boosted their price target on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, BTIG Research boosted their price target on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Trading Up 1.1%

Shares of BSX opened at $97.30 on Monday. The stock’s 50-day moving average is $102.93 and its two-hundred day moving average is $102.06. The stock has a market cap of $144.17 billion, a PE ratio of 57.91, a P/E/G ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the firm posted $0.62 earnings per share. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.